Therapeutic reagents improving FLG function and biologics blocking Th2 cytokines such as anti-IL-4 receptor alpha, anti-IL-4/IL-13 or TSLP [152, 153] are evolving as treatment for severe AD patients. This evidence concerns the gene IL13 and Alzheimer disease.